article · Cancer Research
Abstract Background: Cervical cancer is the fourth leading cause of cancer-related deaths in women worldwide, with high prevalence in South Africa. High-risk human papillomavirus (HPV), along with genetic and epigenetic alterations, drives cervical carcinogenesis. Hypoxia-inducible factor 1-alpha (HIF-1α) is frequently expressed in cervical carcinoma and other solid tumors. Under normoxia, HIF-1α is degraded via the Von Hippel-Lindau pathway, while hypoxia stabilizes it, inducing angiogenic factors. HIF-1α immunohistochemistry has been proposed as a prognostic and therapeutic marker; however, previous studies are limited by small cohorts, single-center designs, and variable histology. This study assessed HIF-1α expression across cervical carcinoma subtypes and its association with tumor aggressiveness. Methods: We conducted a retrospective study of cervical carcinoma cases diagnosed at the University of Pretoria (2017-2022). Archived formalin-fixed paraffin-embedded tissues were retrieved, yielding 63 cases. HIF-1α immunohistochemistry was performed, and three pathologists independently scored staining using a modified quick Allred system, classifying cases as positive if the combined score exceeded zero. Results: HIF-1α expression was positive in 19/63 cases (30%) and negative in 44/63 (70%). Basaloid squamous cell carcinoma accounted for 26% of positive cases, CIN III-like and papillary squamous-urothelial carcinomas each 21%, adenoid basal, papillary squamous, and clear cell carcinomas 10% each, and adenosquamous carcinoma 5%. No adenoid cystic, small cell, or villoglandular carcinomas were positive. Positivity within subtypes was highest in papillary squamous-urothelial (57%) and clear cell (50%) carcinomas, followed by basaloid squamous cell (38%), adenoid basal (33%), CIN III-like and papillary squamous cell (28.5%), and adenosquamous (25%). Conclusion: HIF-1α is expressed in a subset of cervical carcinomas, predominantly in histological variants associated with aggressive behavior, suggesting a potential link with poorer prognosis. Limited sample size and single-center design warrant caution. Larger multicenter studies with clinical follow-up are needed to clarify whether HIF-1α can guide prognostic assessment or targeted therapy in cervical carcinoma. Citation Format: Conwell Ngobeni, Meshack Bida, Benny Mosoane, Rahaba Marima, Tebogo Marutha, Zodwa Dlamini, Tebogo Medupe. Expression of hypoxia-inducible factor 1-alpha in diverse histological types of uterine cervical carcinoma and correlation with the aggressiveness of tumor type: An immunohistochemical study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6328.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1158/1538-7445.am2026-6328
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.